Hampton Creek Press (print and distribution provided by Simon & Schuster) Announces Behind a Closed Door, the Latest Novel by Writer J.D. Barker
April 17, 2024 13:51 ET
|
Hampton Creek Press
The long-awaited thriller from New York Times bestselling author J.D. Barker is available for preorder now and will be released on May 13, 2024.
aTyr Pharma to Participate in April Investor Conferences
April 01, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
Titan Environmental Solutions Inc. Announces Agreement to Purchase Standard Waste Services, LLC
January 16, 2024 08:00 ET
|
Titan Environmental Solutions Inc.
Troy, MI, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Titan Environmental Solutions Inc. ("Titan" or the "Company") (OTCQB: TESI) announced today that the Company signed a Membership Interest Purchase...
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
November 13, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
November 09, 2023 16:00 ET
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023 08:00 ET
|
aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
LLCBuddy Releases Comprehensive Guides for LLC Formation in Any US State
April 12, 2023 09:00 ET
|
LLCBuddy
Cheyenne, WY, April 12, 2023 (GLOBE NEWSWIRE) -- With the increasing number of entrepreneurs and startups across the United States, the demand for a reliable and user-friendly guide to LLC...
“The Life Cycle” Podcast from Klang Games Clarifies the Most Important Questions About the Future of Mankind
April 06, 2023 09:30 ET
|
Klang Games
BERLIN, April 06, 2023 (GLOBE NEWSWIRE) -- Klang Games, the makers behind the sandbox simulation MMO game SEED, are not only concerned with the future of mankind and the colonization of exoplanets...
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
March 20, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its...